Dopaminergic Adverse Events With 24-hour Subcutaneous Infusion of ND0612
Objective: Characterize dopaminergic treatment-emergent adverse events (TEAEs) reported with 24h ND0612 treatment in clinical studies. Background: Dopaminergic adverse events are commonly reported across the spectrum…NouvNeu001, A Phase 1 Stage Chemically Induced Human Dopaminergic Progenitor Cell Therapy for the Treatment of Mid- to Late-stage Parkinson’s Disease
Objective: To access the efficacy and safety of NouvNeu001 in models of Parkinson’s Disease (PD) and a Phase 1 clinical trial (NCT#06167681). Background: Parkinson's disease…ENLITE PD – A Dose Selection Trial of Light Therapy for Impaired Sleep in Parkinson’s Disease
Objective: To determine if either once or twice-daily bright white light therapy (BWLT) improves sleep sufficiently relative to two control LT conditions to warrant proceeding…Lithium Therapy Associated with Reductions in Serum Neurofilament Light Chain (NfL) in Parkinson’s Disease.
Objective: To assess the effects of lithium aspartate and lithium carbonate therapy for 24 weeks on serum NfL in Parkinson’s disease (PD). Background: Lithium has…Changes in Gut Microbiome of Parkinson’s disease Patients using Photobiomodulation Therapy
Objective: To assess changes in the gut microbiome composition in a small cohort of clinical trial participants using photobiomodulation (light therapy) over a five-year period…Assessment of Motor and Non-Motor Alterations Impacting Functionality in Parkinson’s Disease Patients
Objective: To investigate the impact of motor and non-motor changes on the functionality of individuals with Parkinson's disease Background: Parkinson's disease (PD) is the second…Identification of Allosteric GCase Correctors Using Revenir™ for the Treatment of GBA1-Parkinson’s Disease
Objective: To identify novel non-inhibitory allosteric correctors of GCase using Congruence Therapeutic’s in silico proprietary drug discovery engine, Revenir™ Background: GBA1 encoding for glucocerebrosidase (GCase)…In Silico Electrophysiology and System Pharmacology Reveal Coupling Between Dopamine Receptors and Ca2+ Channels in Subthalamic Neuronal Cells towards Parkinson’s Disease
Objective: Recent experimental evidence suggests a potential interaction between dopamine D2 receptors (D2R) and N-type Ca2+ channels, impacting the firing patterns of Subthalamic neuronal (STN)…Comparative-effectiveness of Foscarbidopa/foslevodopa (LDp/CDp) versus Oral Therapies in Advanced Parkinson’s Disease: A Propensity Matched Study
Objective: To assess long-term effectiveness outcomes in people with advanced Parkinson’s Disease (aPD) on LDp/CDp versus those on oral PD therapies (standard of care, SoC).…The Purely Thermodynamic Anti-prionic Mode of Action for the Treatment of Parkinson’s Disease and other Neurodegenerative Diseases
Objective: Demonstration of the anti-prionic MoA for α-synuclein in vitro, PoC in vivo, as well as ex vivo. Background: Neurodegenerative protein-misfolding diseases, like Alzheimer’s (AD)…
- « Previous Page
- 1
- …
- 172
- 173
- 174
- 175
- 176
- …
- 181
- Next Page »